Don't Overlook These 2 Dividend Kings in Today's Volatile Market

Coca-Cola (KO) and Abbott Laboratories (ABT) are presented as stable investment opportunities, recognized as 'Dividend Kings' with 63 and 53 consecutive years of dividend increases, respectively, positioning them as reliable income stocks amidst market volatility. Coca-Cola's resilience is attributed to its diversified beverage portfolio, continuous innovation, and localized manufacturing, while Abbott Laboratories reported strong Q2 revenue growth of 7.5% to $11.1 billion, driven by its medical device segment, notably the FreeStyle Libre franchise, and a robust patent portfolio.

Analysis

In a market environment characterized by volatility stemming from trade policy uncertainty, Coca-Cola (KO) and Abbott Laboratories (ABT) are positioned as stable, income-generating investments due to their status as 'Dividend Kings'. Coca-Cola's resilience is supported by a 63-year history of consecutive dividend increases, a diversified beverage portfolio, and a localized manufacturing model that provides a degree of insulation from tariffs. The company's strategy of continuous product innovation, such as the recent launch of an orange cream-flavored Coca-Cola and a tea-flavored Sprite, is crucial for maintaining its market position against evolving consumer tastes. Abbott Laboratories demonstrates a combination of stability and growth, with 53 consecutive years of dividend growth and a stock price increase of 16% year-to-date. The company's strong financial performance is evidenced by its second-quarter results, where revenue grew 7.5% year-over-year to $11.1 billion, propelled by a 13.4% expansion in its medical device segment. This growth is primarily driven by the FreeStyle Libre continuous glucose monitoring (CGM) franchise, which has a significant long-term growth runway given that less than 1% of the global diabetic population currently has access to CGM technology. Abbott's competitive moat is further solidified by its diversified business across healthcare sectors and a robust patent portfolio affording it pricing power.

Key Decisions for Investors

• For investors prioritizing capital preservation and reliable income in a volatile market, both Coca-Cola and Abbott Laboratories warrant consideration as core holdings due to their long-standing dividend growth and defensive business characteristics.
• Investors with a growth-at-a-reasonable-price (GARP) focus should analyze Abbott's strong performance, specifically its 13.4% growth in medical devices and the substantial untapped market for its FreeStyle Libre franchise, which presents a clear long-term growth catalyst.
• Coca-Cola is best suited for investors seeking stability and consistent income, though the article implies it may not offer the high-growth potential of other market opportunities, making it a potentially less aggressive holding.
• Key performance indicators to monitor are the market penetration rate of Abbott's FreeStyle Libre system and the commercial success of Coca-Cola's new product launches, as these are critical to each company's respective growth and market leadership narratives.